Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

Neurology

Volumn 63, Issue 11, 2004, Pages 2039-2045

  Cree, B A C ^a   Khan, O ^a   Bourdette, D ^a   Goodin, D S ^a   Cohen, J A ^a   Marrie, R A ^a   Glidden, D ^a   Weinstock Guttman, B ^a   Reich, D ^a   Patterson, N ^a   Haines, J L ^a   Pericak Vance, M ^a   DeLa, C ^a   Oksenberg, J R ^a   Hauser, S L ^a  

^a UCSF Multiple Sclerosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; EUROPEAN AMERICAN; FEMALE; GEOGRAPHIC DISTRIBUTION; HAZARD ASSESSMENT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; ONSET AGE; OPTIC NERVE; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPINAL CORD; SURVIVAL; WHEELCHAIR;

EID: 10444231359     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000145762.60562.5D     Document Type: Article

References (46)

1. Bailey P. Incidence of multiple sclerosis in United States troops. Arch Neurol Psychiatry 1922;7:582-583.
2. Alter M. Multiple sclerosis in the Negro. Arch Neurol 1962;7:83-91.
3. Oh SJ, Calhoun CL. Multiple sclerosis in the Negro. J Natl Med Assoc 1969;61:388-392.
4. Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979;29:1228-1235.
5. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004;55:65-71.
6. Foster RM, Harries JR. Multiple sclerosis in the African. Br Med J 1970;3:628.
7. Ames FR, Louw S. Multiple sclerosis in coloured South Africans. J Neurol Neurosurg Psychiatry 1977;40:729-735.
8. Ames FR, Bowen RM. First coloured South African with multiple sclerosis confirmed by necropsy. J Neurol Neurosurg Psychiatry 1979;42:731-733.
9. Kioy PG. Emerging picture of multiple sclerosis in Kenya. East Afr Med J 2001;78:93-96.
10. Modi G, Mochan A, Modi M, Saffer D. Demyelinating disorder of the central nervous system occurring in black South Africans. J Neurol Neurosurg Psychiatry 2001;70:500-505.
11. Haerer AF. Comments on the natural history of multiple sclerosis in Mississippi blacks and whites. University Mich Med Cent J 1976;42:120-123.
12. Alshami E, Jeffery DR. Racial differences in disease severity in patients with multiple sclerosis. Neurology 1998;50:A210.
13. Khan O, Tselis A, Garbern J, Kamholz J, Lisak R. Clinical profile of relapsing multiple sclerosis in African Americans: impact of immunomodulating therapy on disease course. Ann Neurol 1999;46:471-472.
14. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003;9:293-298.
15. Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Multiple sclerosis: severity and progression rate in African Americans compared with whites. Am J Phys Med Rehabil 2003;82:582-590.
16. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998;55:186-192.
17. Osuntokun BO. The pattern of neurological illness in tropical Africa. Experience at Ibadan, Nigeria. J Neurol Sci 1971;12:417-442.
18. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001;56:507-514.
19. Pokroy R, Modi G, Saffer D. Optic neuritis in an urban black African community. Eye 2001;15:469-473.
20. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74:160-167.
21. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
22. Patterson N, Hattangadi N, Lane B, et al. Methods for high-density admixture mapping of disease genes. Am J Hum Genet 2004;74:979-1000.
23. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59: 499-505.
24. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002;125:150-158.
25. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-127.
26. Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002;22:105-122.
27. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
28. Ropper AH, Poskanzer DC. The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms. Ann Neurol 1978;4:51-59.
29. Berman M, Feldman S, Alter M, Zilber N, Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1981;31:966-971.
30. Jeffery DR, Mandler RN, Davis LE. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol 1993;50:532-535.
31. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
32. Clark VA, Detels R, Visscher BR, Valdiviezo NL, Malmgren RM, Dudley JP. Factors associated with a malignant or benign course of multiple sclerosis. JAMA 1982;248:856-860.
33. Poser S, Poser W, Schlaf G, et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986;74:387-392.
34. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-1056.
35. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-782.
36. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999;122:1689-1696.
37. Kira J, Kanai T, Nishimura Y, et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996;40:569-574.
38. Kuroiwa Y, Hung TP, Landsborough D, Park CS, Singhal BS. Multiple sclerosis in Asia. Neurology 1977;27:188-192.
39. Kuroiwa Y, Igata A, Itahara K, Koshijima S, Tsubaki T. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 1975;25:845-851.
40. Shibasaki H, Kuroda Y, Kuroiwa Y. Clinical studies of multiple sclerosis in Japan: classical multiple sclerosis and Devic's disease. J Neurol Sci 1974;23:215-222.
41. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability Brain 1989;112:133-146.
42. Zhang SM, Willett WC, Hernan MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol 2000;152:1056-1064.
43. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-65.
44. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003;61:1122-1124.
45. Cree B, Goodin D, Oksenberg J, Barcellos L, Hauser S. Multiple sclerosis disease activity in patients of different ethnic origin: data from the EVIDENCE trial. Ann Neurol 2003;54:S34.
46. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004;6:66-70.